##common.pageHeaderLogo.altText##

Vol. 3 No. 01 (2023)

Current Aspects of Non Hodgkin Lymphoma (NHL) In Bangladesh: A Mini Review

Clinical Medicine And Health Research Journal, Vol. 3 No. 01 (2023), 15 January 2023 , Page 312-316
https://doi.org/10.18535/cmhrj.v3i01.130

Abstract

Approximately 90% of all lymphomas are classified as non-Hodgkin lymphoma (NHL), a subtype of lymphoma originating in other parts of the immune system outside the lymph nodes. Adult NHL may be classified as either B-cell lymphoma, T-cell lymphoma, or natural killer cell lymphoma, according to the World Health Organization's (WHO) categorization system. According to the statistics, about one and a half million new people are diagnosed with cancer in a year in Bangladesh, among which more than seven thousand people are affected by various blood cancers. Non-Hodgkin and Hodgkin lymphoma, leukaemia, and myeloma belong to blood cancers. Treatment also varies depending on the disease's type and stage or risk. The paper aims to express the current condition of NHL & the treatment approach for this disease by analysing the literature and data of Bangladesh.

Keywords:
  • NHL, Cancer, Lymphomas, Globocan, Bangladesh, etc.

How to Cite

Rahman Bhuiyan, M. K. ., Rahman, D. M. ., Kumar Das, S. ., Shahidul Islam, D. S. M. ., Mahmud, D. F. ., Mukit, A. ., Malik, J. A. ., Ahmed Mahedi, M. R. ., Afrin, S. ., & Syrmos, N. . (2023). Current Aspects of Non Hodgkin Lymphoma (NHL) In Bangladesh: A Mini Review. Clinical Medicine And Health Research Journal, 3(01), 312–316. https://doi.org/10.18535/cmhrj.v3i01.130

Download Citation

References

  • Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence, mortality and prevalence worldwide in 2012: GLOBOCAN 2012 v1.0. Lyon, France: International Agency for Research on Cancer.
  • Story HL, Love RR, Salim R, Roberto AJ, Krieger JL, Ginsburg OM. Improving outcomes from breast cancer in a low-income country: lessons from Bangladesh. Int J Breast Cancer. 2012.
  • Wasim BH, Mohammad AM. State of cancer care in Bangladesh. The Daily Star. 2022.
  • Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB, Parihar AS, Sharma U. Non-Hodgkin's lymphoma: A review. J Family Med Prim Care. 2020 Apr 30;9(4):1834-1840. http://doi.org/10.4103/jfmpc.jfmpc_1037_19
  • Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018; 362, 3204.
  • Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma-A review. Acta Oncol. 2006; 45: 258–71.
  • Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, et al. Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: A clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 99: 303–10.
  • Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, Miah MM, Kabir AL, Islam N, Dipta TF, Rahman F, Mottalib A, Afrose S, Ara T, Biswas AR, Rahman M, Abedin AM, Rahman M, Yunus AB, Niessen LW, Sultana TA. Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC Cancer. 2014; 14:438. http://doi.org/10.1186/1471-2407-14-438.
  • Jensen OM, Storm HH. Purposes and uses of cancer registration. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG (eds). Cancer registration: principles and methods. IARC scientific publication 95. Lyon: International Agency for Research on Cancer, 1991: 7-21.
  • Coleman M, Wahrendore J, Demaret E (eds). Directory of on-going research in cancer epidemiology. IARC scientific publication 117. Lyon: International Agency for Research on Cancer, 1992: 7-21.
  • Rahid S.M, Hafiza L,, Durba H, Shahjada. Hematological Malignancies Pattern among Bangladeshi Adult. Jour Med Sci Clin Res. 8(5), 2020.
  • Shariful A. Cancer Registry and Its Different Aspects. J Enam Med Col 2011; 1(2): 76-80.
  • Karmali R.Rituximab: A benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Ann onco, 2021, 29(2), 332-340, http://doi.org/10.1093/annonc/mdx768
  • Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged clinical and Molecular remission in patients with low-grade or Follicular Non-Hodgkin's Lymphoma treated With Rituximab plus CHOP chemotherapy: 9-Year Follow-Up. Jour Clin Onco, 2004, 22(23), 4711-4716, http://doi.org/10.1200/jco.2004.04.020
  • Fanale M, Younes A. Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma, Adis Data Information BV. The University of Texas M.D. Anderson Cancer Center. 2007.
  • MH van Oers, Klasa R, Marcus RE. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood, 2006, 108(10), 3295-3301.
  • Visser J. Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab. Bio Drugs, 2013, 27, 495-507.
  • Sharman J. A randomized, double-blind efficacy and safety study of PF-05280586 (a potential rituximab biosimilar) compared with rituximab reference product (Mabthera®) in subjects with previously untreated CD20-positive, low tumor burden follicular lymphoma (LTB-FL) Blood, 2018. 394, http://doi.org/10.1182/blood-2018-99-111248
  • Robak T. New anti-cd20 monoclonal antibodies for the treatment of b-cell lymphoid malignancies. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011, 25(1), 13-25, http://doi.org/10.2165/11539590-000000000-00000
  • Cai P, Hao J, Wang D, Xu J. Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta analysis. Oncotarget. 2017 Aug 24;8(53):91238-91247. http://doi.org/10.18632/oncotarget.20437.
    • Article Viewed: 0 Total Download

    ##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##

    Cover Image

    Information